NCT07132515RecruitingPhase 4
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 20 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 10 Aug 2025
- Start date
- 15 Aug 2023
- Primary completion date
- Aug 2025
- Lead sponsor
- Mansoura University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07132515
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 15 Aug 2023 to the primary completion date, Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Who the study is looking for
- Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mansoura University Hospitals Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.